Cardiovascular Systems, Inc. (CSII)
Market Cap | 636.66M |
Revenue (ttm) | 244.71M |
Net Income (ttm) | -32.53M |
Shares Out | 40.79M |
EPS (ttm) | -0.84 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 443,757 |
Open | 14.90 |
Previous Close | 14.74 |
Day's Range | 14.40 - 15.64 |
52-Week Range | 14.12 - 44.57 |
Beta | 0.91 |
Analysts | Buy |
Price Target | 22.95 (+47.0%) |
Earnings Date | May 4, 2022 |
About CSII
Cardiovascular Systems, Inc., a medical device company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products, which are catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Corona... [Read more...]
Financial Performance
In 2021, CSII's revenue was $258.97 million, an increase of 9.48% compared to the previous year's $236.55 million. Losses were -$13.42 million, -50.72% less than in 2020.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for CSII stock is "Buy." The 12-month stock price forecast is 22.95, which is an increase of 47.02% from the latest price.
News

Cardiovascular Systems' (CSII) Q3 Earnings Top Estimates
Cardiovascular Systems' (CSII) third-quarter revenues declined year over year due to lower Coronary and peripheral revenues.

Cardiovascular Systems (CSII) Reports Q3 Loss, Lags Revenue Estimates
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of 10.71% and 2%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems, Inc. Reports Fiscal 2022 Third Quarter Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients wit...

Cardiovascular Systems (CSII) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Cardiovascular Systems (CSII) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 Medical Product Stocks Poised to Beat This Earnings Season
Medical product companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how ALC, ZBH and CSII are poised ahead of their earnings releases.

Here's Why You Should Hold on to Cardiovascular Systems (CSII)
Investors are optimistic about Cardiovascular Systems' (CSII) robust international growth and upcoming launches.

Cardiovascular Systems, Inc. to Host Earnings Conference Call on May 4, 2022
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO HOST EARNINGS CONFERENCE CALL ON MAY 4, 2022

Cardiovascular Systems, Inc. to Participate at Two Upcoming Healthcare Conferences
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PARTICIPATE AT TWO UPCOMING HEALTHCARE CONFERENCES

Cardiovascular Systems, Inc. Announces First In-Human Experience With Company's Propel™ Percutaneous Ventricular Assi...
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. ANNOUNCES FIRST IN-HUMAN EXPERIENCE WITH COMPANY'S PROPEL™ PERCUTANEOUS VENTRICULAR ASSIST DEVICE

Cardiovascular Systems' (CSII) Low Procedure Volume Dents Sales
Cardiovascular Systems (CSII) notes that recovery from the Delta variant has been suppressed by the emergence of the highly contagious Omicron variant.

Cardiovascular Systems (CSII) Finances New DCB Development
Per the terms of the deal, Cardiovascular Systems (CSII) is providing milestone-based financing to CVT for the development of coronary and peripheral DCBs.

Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Announces First In-Human Experience With Peripheral Everolimus Drug-Coated Balloon

Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D.
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Appoints Jeffery W. Chambers, M.D., as Chief Medical Officer.

3 Moonshot Stocks Insiders Are Buying. What Do They Know?
Biotech stocks aren't a sure thing, but one good sign is insiders buying up shares. These three all offer that enticing feature.

Cardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy De...
ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. Announces Partnership With Innova Vascular, Inc. to Develop Full Line of Thrombectomy Devices

Cardiovascular Systems' (CSII) Q2 Earnings Lag Estimates
Cardiovascular Systems (CSII) exhibits a robust performance by its worldwide coronary franchise despite challenging business climate.

Cardiovascular Systems (CSII) Reports Q2 Loss, Misses Revenue Estimates
Cardiovascular Systems (CSII) delivered earnings and revenue surprises of -64.29% and 5.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cardiovascular Systems, Inc. Reports Fiscal 2022 Second Quarter Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2022 SECOND QUARTER FINANCIAL RESULTS

Cardiovascular Systems, Inc. to Participate at SVB Leerink 2022 Global Healthcare Conference
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. TO PARTICIPATE AT SVB LEERINK 2022 GLOBAL HEALTHCARE CONFERENCE

Cardiovascular Systems, OrbusNeich Scores FDA Approval For Scoreflex Scoring Balloon
Cardiovascular Systems Inc (NASDAQ: CSII), along with OrbusNeich Medical Company Ltd, have received FDA PMA approval for OrbusNeich's Scoreflex NC Scoring Percutaneous Transluminal Coronary Angioplasty ...

Cardiovascular Systems, Inc. and OrbusNeich Announce FDA PMA Approval of Scoreflex® Scoring Balloon
ST. PAUL, Minn.--(BUSINESS WIRE)--CARDIOVASCULAR SYSTEMS, INC. AND ORBUSNEICH ANNOUNCE FDA PMA APPROVAL OF SCOREFLEX® SCORING BALLOON

Cardiovascular Systems (CSII) Expands Lithotripsy Technology
Cardiovascular Systems (CSII) has developed intravascular lithotripsy systems to treat calcific coronary and peripheral artery diseases.

Cardiovascular Systems To Develop IVL Technology For Coronary, Peripheral Artery Diseases
Cardiovascular Systems Inc (NASDAQ: CSII) has announced the development of intravascular lithotripsy (IVL) technology for coronary and peripheral artery diseases. Enrolling patients in an investigationa...

Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coron...
ST. PAUL, Minn.--(BUSINESS WIRE)--CSI ANNOUNCES DEVELOPMENT OF INTRAVASCULAR LITHOTRIPSY TECHNOLOGY FOR THE TREATMENT OF CORONARY AND PERIPHERAL ARTERY DISEASES

Cardiovascular Systems (CSII) Coronary Sales Up Amid COVID Woe
Cardiovascular Systems (CSII) continues to experience strong demand for physician training and certification in all international markets.